Intangible assets, in-process research and development and goodwill (Tables)

12 Months Ended

Dec. 31, 2015

Intangible assets, in-process research and development and goodwill [Abstract]

Intangible assets consisted of the following:

	Biodefense			Biosciences
(in thousands)	Segment			Segment			Total
Cost basis
Balance at December 31, 2014	$	48,799		$	19,500		$	68,299
Additions		-			8,300			8,300
Balance at December 31, 2015	$	48,799		$	27,800		$	76,599

Accumulated amortization
Balance at December 31, 2014	$	(7,820	)	$	(2,135	)	$	(9,955	)
Amortization		(6,209	)		(3,060	)		(9,269	)
Balance at December 31, 2015	$	(14,029	)	$	(5,195	)	$	(19,224	)

Net book value at December 31, 2015	$	34,770		$	22,605		$	57,375

Finite-lived Intangible Assets Amortization Expense

Amortization expense consisted of the following:

	December 31,
(in thousands)	2015		2014		2013

Biodefense segment	$	6,209	$	5,869	$	1,951
Biosciences segment		3,060		2,135		-
Total amortization expense	$	9,269	$	8,004	$	1,951

As of December 31, 2015, the weighted average amortization period remaining for intangible assets in the Biodefense and Biosciences segments was 88 and 90 months, respectively.

Future Amortization Expense

Future amortization expense as of December 31, 2015 is as follows:

(in thousands)
2016	$	8,976
2017		8,300
2018		8,300
2019		7,821
2020 and beyond		23,978
Total remaining amortization	$	57,375

Goodwill

The following table is a summary of changes in goodwill by reporting unit:

(in thousands)	Biosciences therapeutics		Biosciences contracts manufacturing		Biodefense therapeutics and vaccines		Biodefense medical device(s)		Total
Cost Basis
Balance at December 31, 2014	$	13,902	$	6,736	$	22,031	$	9,916	$	52,585
Additions		-		-		2,317		-		2,317
Balance at December 31, 2015	$	13,902	$	6,736	$	24,348	$	9,916	$	54,902